Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline

Abbreviations: 17OHP, 17-hydroxyprogesterone; nl, normal; P4, progesterone; PRL, prolactin; T, testosterone.

Authors and Disclosures

Catherine M. Gordon¹, Kathryn E. Ackerman^2,5, Sarah L. Berga³, Jay R. Kaplan³, George Mastorakos⁴, Madhusmita Misra⁵, M. Hassan Murad⁶, Nanette F. Santoro⁷ and Michelle P. Warren⁸

¹Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229; ²Boston Children's Hospital, Boston, Massachusetts 02115; ³Wake Forest School of Medicine, Winston-Salem, North Carolina 27157; ⁴Areteio Hospital, Medical School, National and Capodistrian University of Athens, Athens, Greece 10674; ⁵Massachusetts General Hospital, Boston, Massachusetts 02114; ⁶Division of Preventive Medicine, Mayo Clinic, Rochester, Minnesota 55905; ⁷University of Colorado School of Medicine, Aurora, Colorado 80045; and ⁸Center for Menopause, Hormonal Disorders, and Women's Health, Columbia University Medical Center, New York, New York 10021

Address all correspondence and requests for reprints to
The Endocrine Society, 2055 L Street NW, Suite 600, Washington, DC 20036. E-mail: publications@endocrine.org; Phone: 202-971-3636.

Financial Disclosures of the Task Force*
Catherine M. Gordon (chair)—Financial or Business/Organizational Interests: Janssen Pharmaceuticals (member, data safety monitor board): Department of Justice, Health Resources and Services Administration (consultant), National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development (council member), Significant Financial Interest or Leadership Position: none declared. Kathryn E. Ackerman—Financial or Business/Organizational Interests: Walden Behavioral Care Eating Disorder Treatment Center (clinical advisory board), Significant Financial Interest or Leadership Position: Walden Behavioral Care Eating Disorder Treatment Center (clinical advisory board). Sarah L. Berga—Financial or Business/Organizational Interests: Ferring Pharmaceuticals Inc. (consultant), Vermillion Pelvic Mass Registry (advisory panel), What's My Fertility (advisory board), American College of Obstetrics and Gynecology (editorial board), American Journal of Obstetrics and Gynecology (editorial board), International Society for Gynecological Endocrinology (editorial board), Menopause (editorial board), Society for Women's Health Research (editorial board), Ferring Pharmaceuticals Inc. (principal investigator), National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant/consultant), National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant), National Institutes of Health/National Cancer Institute (grant/principal investigator), National Institutes of Health/Office of the Director (grant), Significant Financial Interest or Leadership Position: none declared. Jay R. Kaplan—Financial or Business/Organizational Interests: none declared, Significant Financial Interest or Leadership Position: none declared. George Mastorakos—Financial or Business/Organizational Interests: European Society of Endocrinology (ex official member of executive committee), Hellenic Endocrine Society (president), Significant Financial Interest or Leadership Position: European Society of Endocrinology (ex official member of executive committee), Hellenic Endocrine Society (president). Madhusmita Misra—Financial or Business/Organizational Interests: none declared, Significant Financial Interest or Leadership Position: none declared. M. Hassan Murad**—Financial or Business/Organizational Interests: The Mayo Clinic, Division of Preventive Medicine, Significant Financial Interest or Leadership Position: none declared. Nanette F. Santoro—Financial or Business/Organizational Interests: Bayer, Inc. (grant investigator, initiated grant support), Menogenix (ownership interest), Significant Financial Interest or Leadership Position: none declared. Michelle P. Warren—Financial or Business/Organizational Interests: Pfizer (grantee), Significant Financial Interest or Leadership Position: none declared.
*Financial, business, and organizational disclosures of the task force cover the year prior to publication. Disclosures prior to this time period are archived.
**Evidence-based reviews for this guideline were prepared by the Mayo Clinic, Division of Preventive Medicine, under contract with the Endocrine Society.